use of neurovitan in the treatment of endocrine polyneuropathy
Clicks: 134
ID: 185303
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
134 views
27 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #60 of 79 articles by views in Macromolecular rapid communications
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Neurovitan may be the drug of choice in the implementation of complex therapy of neurotropic vitamins in patients with endocrine pathology. Objectiv: to study the effectiveness of Neurovitan in the complex treatment of endocrine polyendocrinopathy. Materials and methods: we examined 18 patients with diabetes mellitus and 15 patients with hypothyroidism. All patients were diagnosed distal polyneuropathy of the hands and feet. The drug Neurovitan took all patients 1 table. 4 times a day for 2 months. Conclusions: the use of the drug Neurovitan in the treatment of patients with diabetes and hypothyroidism can prevent violations that are a consequence of polyneuropathy.
| Reference Key |
vlasenko2014mnarodnijuse
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;M.V. Vlasenko;A.V. Palamarchuk;A.V. Golovan |
| Journal | Macromolecular rapid communications |
| Year | 2014 |
| DOI |
10.22141/2224-0721.3.59.2014.76608
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.